Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer Drug

Bristol-Myers Squibb

John Greim / Contributor / Getty Images

Key Takeaways

  • Bristol-Myers Squibb and 2seventy bio shares dropped after the FDA said it would not make a decision on expanded use of the companies' cancer drug next month.
  • The treatment has already been approved by regulators to treat adults who haven't responded to other medicines.
  • A decision by Bayer to end its study of an experimental blood-thinning medicine could also impact the future of a similar drug being tested by Bristol-Myers Squibb and Janssen Pharmaceuticals.

Shares of Bristol-Myers Squibb (BMY) and partner 2seventy bio (TSVT) slumped after the two companies announced that the Food and Drug Administration (FDA) would not make a decision on expanded use for their blood cancer treatment, Abecma, next month as originally planned.

The FDA was set to decide on Dec. 16 whether Abecma could be prescribed for those with earlier lines of triple-class exposed relapsed or refractory multiple myeloma. Regulators had already approved Abecma to treat adult patients with multiple myeloma after four or more previous treatments weren’t effective.

Bristol-Myers Squibb and 2seventy bio indicated they anticipate officials would be reviewing data related to the secondary endpoint of overall survival rates in their Phase 3 study of Abecma. They added they “looked forward to continuing discussions with the FDA,” as well as participating in the meeting of the FDA’s Oncologic Drug Advisory Committee that will be analyzing the results.?

A decision by Germany’s Bayer to end a Phase 3 trial of an experimental blood-thinning medicine because of lack of efficacy also raised concerns about the future of a similar medicine under development by Bristol-Myers Squibb and Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals.

Bristol-Myers Squibb shares dropped over 2% Monday to their lowest level since the beginning of the COVID-19 pandemic, while 2seventy bio shares sank more than 16% to their all-time low.



Do you have a news tip for Investopedia reporters? Please email us at
Article Sources
Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.
  1. Bristol-Myers Squibb. "Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma."

  2. Bayer. "OCEANIC-AF study stopped early due to lack of efficacy."

Take the Next Step to Invest
The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.